Clinical Report: Equal Pay in Ophthalmology? Not Yet
Overview
A recent study reveals that women academic ophthalmologists earned only 85 to 91 cents for every dollar earned by their male counterparts in 2024. While compensation parity may be achievable at lower academic ranks, it remains elusive at higher levels such as professor and department chair.
Background
Gender pay disparity in medicine is a significant issue, particularly in specialized fields like ophthalmology. Understanding compensation trends is crucial for addressing inequities that affect career advancement and financial stability for female ophthalmologists. This study provides a comprehensive analysis of compensation trends over several years, highlighting persistent disparities.
Data Highlights
Rank
Male Compensation
Female Compensation
Female per Male Dollar
Assistant Professor
$324,000
$296,000
$0.91
Associate Professor
$411,000
$350,000
$0.85
Professor
$445,000
$377,000
$0.85
Department Chair
$761,000
$696,000
$0.91
Key Findings
Women earned 85 to 91 cents for every dollar earned by men in 2024 across academic ranks.
Median total compensation increased from 2016 to 2024, but only assistant professor salaries modestly exceeded inflation.
Women comprised 52% of assistant professors but only 19% of department chairs in 2024.
Projected career earnings gap over 30 years is $1.04 million, with women earning 87 cents per male dollar cumulatively.
Parity in compensation is projected to be achievable within 7.5 years for assistant professors and 14.6 years for associate professors, but not for higher ranks.
Clinical Implications
Healthcare institutions should implement structured and transparent compensation systems to address gender disparities in pay. Regular salary audits and equalization of starting salaries can help mitigate inequities and promote a more equitable work environment for all faculty members.
Conclusion
The findings underscore the ongoing challenges of gender pay equity in academic ophthalmology, necessitating systemic changes to ensure fair compensation across all ranks.
The combination of photodynamic therapy and intravitreal aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.
